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R E V I E W A R T I C L E
Primaquine Therapy for Malaria
J. Kevin Baird and Stephen L. Hoffman
1US Naval Medical Research Center Detachment, Lima, Peru, and 2Sanaria, Rockville, Maryland
Primaquine is the only available drug for preventing relapse of malaria, and confusion surrounds its use. This
review examines the wide range of clinical applications of primaquine described in the medical literature
between 1946 and 2004. The risk of relapse of Plasmodium vivax malaria without primaquine therapy ranged
from 5% to 80% or more, depending largely upon geographic location. Supervision of therapy profoundly
impacts the risk of relapse, and almost all reports of malaria resistant to primaquine are associated with lack
of such supervision. We nonetheless suspect that there is widespread resistance to the standard course of
primaquine therapy, which is 15 mg primaquine base daily for 14 days. Clinical evidence confirms that a
course of 15 mg daily for just 5 days, a regimen widely used in areas where malaria is endemic, has no
discernible efficacy. This review supports a recommendation for a regimen of 0.5 mg/kg primaquine daily for
14 days, on the basis of superior efficacy and good tolerability and safety in nonpregnant persons without
glucose-6-phosphate dehydrogenase deficiency.
Malaria causes an acute, debilitating febrile syndrome
that ends in death for 1.5–2.7 million of the ∼500 mil-
lion infected annually [1]. Just 100 years ago, malaria
infected millions of people in North America, Europe,
Australia, and other subtropical and temperate regions
[2]. Chloroquine, primaquine, and dichlorodiphenyl-
trichloroethane (DDT) helped eradicate malaria from
temperate latitudes and control it in the tropics [3].
Those gains have deteriorated substantially, and out-
breaks occur even in the United States [4–7].
Primaquine, introduced in 1950, prevents relapse and
sterilizes infectious sexual plasmodia, but confusion sur-
rounds its use. Among the several widely used regimens,
none has been adequately evaluated. Tolerance of pri-
maquine by Plasmodium vivax occurs in Southeast Asia
and Oceania, but the risk of therapeutic failure has been
rarely documented anywhere. Poor adherence to pri-
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maquine therapy and resistance to companion drugs like
chloroquine, compounds the confusion. Worse still, ab-
breviated regimens of primaquine without proven clin-
ical efficacy are also widely used. Finally, available evi-
dence refutes primaquine’s reputation for being toxic and
poorly tolerated. This review examines these issues.
BIOLOGY
The protozoa that cause malaria belong to the apicom-
plexid coccidian family Plasmodiidae, genus Plasmo-
dium. The genus contains 172 species, but only 4 rou-
tinely infect humans: Plasmodium falciparum, P. vivax,
Plasmodium malariae, and Plasmodium ovale. Other
plasmodia infect mammals, birds, and reptiles, and
these rarely infect humans [8]. The plasmodia follow
a similar life cycle (figure 1). The most important dis-
tinction between the 4 different Plasmodium species
that bears on therapy is that 2 can cause relapse—
parasitemia originating from hypnozoites in the liver
that occurs from 16 days to several years after the pri-
mary infection. Only P. vivax and P. ovale form hyp-
nozoites. Latent blood stages of the parasite account for
the chronicity of malaria due to P. malariae, and malaria
due to P. falciparum typically exhibits no chronic latency.
P. vivax is pantropical, but it is largely absent from
Africa. Black Africans lack an erythrocyte surface pro-
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Figure 1. Life cycle of Plasmodium species in human beings. Plasmodium vivax and Plasmodium ovale produce both primary tissue schizonts and
the hypnozoite that leads to a secondary tissue schizont, whereas Plasmodium falciparum and Plasmodium malariae produce only a primary tissue
schizont. Parasitemia arising from hypnozoites is called a “relapse,” and P. vivax and P. ovale malaria are called the “relapsing malarias.” Primaquine
treatment is often called “anti-relapse” therapy.
tein called Duffy factor that P. vivax merozoites require for
invasion. Vivax malaria is especially common in India, Indo-
china, and the Philippine, Indonesian and New Guinean ar-
chipelagos. In the New World, vivax malaria occurs from north-
ern Mexico to northern Argentina. Endemic P. ovale malaria
occurs only in West Africa, The Philippines, Eastern Indonesia,
and Papua New Guinea.
RELAPSE
Primaquine prevents relapse of malaria [9]. The pattern and
probability of relapse in the absence of primaquine therapy
varies by geographic origin. P. vivax malaria in temperate
regions relapses at long intervals (16 months) [10]. Among
1021 soldiers infected with P. vivax in Korea, 32% had relapse
[11–14]. In India, the 12-month relapse rate ranged from 9%
to 19% [15, 16]. All 180 subjects challenged with the North
American St. Elizabeth strain of P. vivax had relapse 6–12
months later [17]. Experimental challenge notwithstanding, in
temperate regions, the odds of relapse of P. vivax malaria are
approximately 1 in 4 (table 1).
Infection with tropical strains of P. vivax is associated with
a higher probability of relapse, relapse that occurs sooner, and,
typically, multiple relapses. Among 54 American soldiers in-
fected in the Pacific, all experienced relapse within 3 months
[19]. Similar cohorts including a total of 562 subjects had a 5-
month relapse rate of 72% [20, 21]. Of 213 subjects experi-
mentally challenged with the Chesson strain of P. vivax from
New Guinea [27], 99% had relapse within 8 months, most
within 1 month after the primary parasitemia [17, 18]. Among
333 subjects infected with P. vivax from the tropical Pacific,
the median time of relapse was day 22 after onset of the primary
parasitemia [28]. No relapse occurred before day 16.
The probability of relapse is high (11 in 5), regardless of where
the infection is acquired, and potential exposure to infection
indicates use of terminal prophylaxis (i.e., presumptive prima-
quine therapy). Indeed, failure to prescribe or comply with post-
exposure prophylaxis accounts for most cases of vivax malaria
in travelers [29]. Schwartz et al. [30] found that late onset (12
months after exposure) occurred in 62% of 1321 vivax malaria
cases, and in 63% of these cases, there was adequate adherence
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Table 1. Summary of reports of relapse of Plasmodium vivax malaria not treated with
primaquine therapy.
Reference(s)
Geographic
location
P. vivax
strain
No. of
patients
Duration of
follow-up
Percentage
of patients
with relapse
[17, 18] New Guinea Chesson 213 2 w to 18 mo 99
[19] New Guinea Wild 54 2 w to 3 mo 100
[20, 21] Pacific Wild 562 2–5 mo 72
[12–14] Korea Wild 1021 14 mo 32
[16] India Wild 264 2–8 mo 19
[15] India Wild 5528 12 mo 11
[22] India Wild 222 12 mo 9
[23] Pakistan Wild 250 12 mo 52
[24] Thailand Wild 342 2 mo 63
[25] Ethiopia Wild 29 3 mo 50
[17] North America St. Elizabeth 180 12 mo 100
[26] Global Wild 68 NR 25
NOTE. Mo, months; NR, not reported; w, weeks.
to prescribed suppressive prophylaxis (i.e., against blood stages
of the parasite). Most cases of vivax malaria among travelers are
relapses and are preventable with primaquine, the only currently
available drug for therapy to prevent relapse.
PRIMAQUINE THERAPY
Development. War in the Pacific in 1941 created an urgent
strategic need in the United States for a drug to prevent relapse
of malaria. Studies during and after World War II focused on
8-aminoquinolines, because, in the 1920s, pamaquine (the pro-
totypical 8-aminoquinoline) had proven effective but too toxic.
Thousands of compounds were screened in animals, and 21
went to clinical trials. Isopentaquine and primaquine proved
superior [31]. Primaquine became available to American troops
during the Korean War.
A total dose of 200 mg primaquine base (all doses of pri-
maquine in this article refer to base, exclusive of weight of the
typical diphosphate salt formulation) achieved cure, and a dose
of 15 mg was well tolerated, so a 14-day regimen was adopted.
According to Schmidt et al. [32], “the use of this regimen should
not be construed as synonymous with necessity” (p. 1127). Pro-
vided an adequate total dose was delivered, schedule did not
impact efficacy. A single 45-mg dose administered once per week
for 8 weeks (360 mg) was as effective as 30 mg daily for 14 days
(420 mg) or 60 mg daily for 7 days (420 mg) [33] and was more
effective than 15 mg daily for 14 days (210 mg) [34].
Pharmacokinetics. Primaquine is rapidly absorbed in the
gastrointestinal tract and concentrated in the liver, brain, heart,
lungs, and skeletal muscle. It crosses the placenta. The mean
volume of distribution is 3 L/kg. It peaks in plasma within 1–
3 h, at ∼70 mg/mL. It is rapidly excreted in urine, with a plasma
half-life of 4–9 h. Its metabolism is complex and poorly un-
derstood [35]. Among the many known or suspected metab-
olites, none has been definitively linked to activity against the
Plasmodium parasite.
Standard therapy. Primaquine therapy is given after the
diagnosis of P. vivax or P. ovale malaria and should coincide
with blood schizonticidal therapy. Others recommend com-
mencing primaquine therapy after blood schizonticidal therapy,
on the basis of immunosuppressive activity observed in vitro
[36–38]. In vivo studies have failed to corroborate those find-
ings [39]. Primaquine appears to be more effective when given
concurrently with blood schizonticides [40–42] (table 2). In-
donesians who took 30 mg daily for 1 year showed no effects
on cellular immunity to tetanus toxoid [43] or on susceptibility
to malaria [44].
A few studies during the past 25 years gauged therapeutic
efficacy of standard primaquine therapy [45–55]. Reports up
to 1977 confirmed the excellent efficacy of supervised therapy
against P. vivax infection in regions other than New Guinea
and Thailand (table 3). Of 1344 patients given supervised ther-
apy, only 14 (1%) experienced relapse, whereas, of 2061 patients
given unsupervised therapy, 449 (22%) had relapse (relative
risk, 0.05; 95% CI, 0.03–0.09; ). Similarly, the relativeP ! .0001
risk of relapse with supervised therapy among 469 soldiers
returned from Vietnam was 0.23 (95% CI, 0.12–0.46; P! .0001).
Relapse after unsupervised therapy [56, 58–67] does not prove
resistance.
Nonetheless, primaquine does not remain universally effec-
tive. During the past 10 years, we heard from clinicians around
the world complaining of more frequent failures of primaquine
therapy. Even though no unambiguous evidence of resistance
yet exists, experience teaches us to heed such warnings. We
routinely advise against using the standard regimen and instead
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Table 2. Summary of relapse rates after standard primaquine therapy in early reports of
infection with the Chesson strain of Plasmodium vivax.
Reference Primaquine dosage
Concurrent
blood
schizonticidal
therapy
No. of
patients
Duration of
follow-up,
months
Percentage
of patients
with relapse
[41] 15 mg/day for 14 days None 19 12 79
[18] 15 mg/day for 14 days Quinine 24 12 21
[34] 15 mg/day for 14 days Chloroquine 79 12 27
[18] 22.5 mg/day for 14 days None 5 12 80
[18] 22.5 mg/day for 14 days Quinine 31 12 3
[18] 30 mg/day for 14 days Quinine 5 12 0
[33] 60 mg/day for 7 days Chloroquine 11 1–14 0
[34] 45 mg/week for 8 weeks Chloroquine 71 12 8
recommend the alternative of 0.5 mg/kg daily for 14 days. This
now concurs with recommendations by the Centers for Disease
Control and Prevention (unpublished data, CDC).
Failure of standard therapy. Evidence for failure of the
standard primaquine regimen emerged from early experimental
challenge with the Chesson strain of P. vivax isolated from an
American soldier infected in New Guinea in 1944 [27]. Table
2 summarizes that work of 50 years ago. Relapse occurred in
26 of 103 subjects treated with chloroquine or quinine and the
standard primaquine regimen of 15 mg, whereas only 1 of 36
subjects treated with primaquine regimens of 22.5 or 30 mg
daily for 14 days had relapse. The relative risk associated with
the higher dose was 0.11 (95% CI, 0.02–0.78; ). MoreP ! .005
recent trials in Thailand demonstrated similar findings: 7 (18%)
of 81 patients given a standard dosage of chloroquine and a
15-mg primaquine regimen had relapse within 6 months,
whereas only 1 of 86 treated with a 22.5-mg regimen had relapse
[46]. In the other study [47], 10 (17%) of 60 patients given
standard primaquine therapy had relapse. The relative risk of
relapse associated with the 22.5-mg regimen, compared with
the 15-mg regimen, was 0.1 (95% CI, 0.01–0.71; ). AP ! .005
trial found that a regimen of 30 mg daily for 14 days combined
with atovaquone and proguanil (Malarone; GlaxoSmithKline)
was efficacious against P. vivax infection in 46 Thai patients,
of whom 35 were followed up for 12 weeks, and there were
just 2 cases of recurrent parasitemia (94% efficacy) [68]. Jelinek
et al. [59] demonstrated that infection acquired on the island
of New Guinea had a 12-fold higher risk of relapse after pri-
maquine therapy. Only 3 of 44 who did not travel to New Guinea
experienced relapse, whereas 4 of 5 persons who did travel to
New Guinea experienced relapse (OR, 11.7; 95% CI, 1.6–100;
). Duarte et al. [69] report the only recent study of ther-P ! .001
apeutic response to standard primaquine therapy among patients
with vivax malaria in the New World: 7 (14%) of 50 patients
given supervised therapy had relapse within 6 months.
Vivax malaria should be treated with a primaquine regimen
of 22.5 mg daily for 14 days (we favor 30 mg), or a total
dose of 315 mg for as long as 8 weeks [29, 42, 43, 48, 49].
Schwartz and colleagues [70] demonstrated a high risk of re-
lapse after standard “adult-dose” therapy (15 mg daily for 14
days) among Israeli patients weighing 180 kg. Medical officers
of the New Zealand armed forces described the same phenom-
enon among troops who returned from East Timor (unpub-
lished data). Patients heavier than 70 kg should receive at least
0.5 mg/kg daily.
For patients who are pregnant or who have well-documented
failure of recommended primaquine therapy, no currently
available alternative therapies exist. The risk of relapse in these
patients should be managed with suppressive therapy with chlo-
roquine or mefloquine for at least 4 weeks, preferably 8 weeks.
These patients certainly should be counseled regarding their
risk of relapse beyond 8 weeks.
Resistance to primaquine. Resistance to primaquine by
blood stages of the Plasmodium parasite [71] is of little clini-
cal consequence. Resistance in tissue stages dominates public
health concern, and the absence of such resistance after 50 years
seems incredible. There may be compelling physical, chemical,
or biological reasons; for example, short plasma half-life or
sterilization of gametocytes. Alternatively, clinical evidence of
resistance to primaquine may be present but difficult to detect.
We favor this explanation.
Proof of resistance requires addressing important confound-
ing factors. Use of directly observed therapy administered by
reliable people addresses the most important of these. Patients
exposed to risk of infection after treatment should be excluded
from analysis. Resistance to chloroquine by P. vivax [72–75]
must be considered; recurrent parasitemia may be recrudes-
cence of a chloroquine-resistant strain, rather than relapse due
to a primaquine-resistant strain. Clinical trials designed to de-
tect resistance to primaquine should use an effective blood
schizonticide with a short plasma half-life, such as quinine,
which will rule out the possibilities of suppression of early
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Table 3. Summary of reports of relapse of Plasmodium vivax malaria after treat-
ment with a standard regimen of primaquine therapy (15 mg per day for 14 days).
Type of therapy,
geographic location Year
No. of
patients
Duration of
follow-up,
months
Percentage
of patients
with relapse Reference(s)
Supervised
Vietnam 1974 218 12 4 [45]
Thailand 1994 141 1–18 18 [46, 47]
Solomon Islands 1977 10 12 0 [48]
Korea 1953 914 4–20 !1 [49, 50]
Nicaragua 1953 145 4 0 [51]
Central America 1974 57 9–36 4 [52]
Unsupervised
Vietnam 1970 251 12 18 [53, 54]
Brazil 1991 1347 3–12 25 [55]
Somalia 1997 60 NR 43 [29]
Global 1995 57 118 13 [59]
Global 1987 175 NR 10 [26]
Global 1990 132 NR 9 [57]
NOTE. Mo, months; NR, not reported.
relapse by lingering traces of the drug in patients (i.e., false-
negative responses) and recrudescence due to resistance to chlo-
roquine (i.e., false positive responses). Table 4 summarizes key
confounders of the diagnosis of infection with primaquine-
resistant P. vivax. Collins and Jeffery [76] have reviewed resis-
tance to and tolerance of primaquine in P. vivax.
Five-day regimen. A primaquine regimen of 15 mg daily
for 5 days to prevent relapse of P. vivax malaria is national
policy in many countries where the disease is endemic. In 1954,
Singh et al. [77] found no cases of relapse among 50 patients
treated with pyrimethamine and the 5-day regimen. Basavaraj
[78] corroborated this in 1960, as did Mendoza in Mexico
(World Health organization document WHO/MAL/527.65,
cited by Contacos et al. [79]). Cedillos et al. [80] found re-
ductions in the number of clinical episodes in communities
where the 5-day regimen plus standard amodiaquine was given.
Some studies showed low relapse rates (!10%) among large
numbers of patients in India given the 5-day regimen [22, 81],
but relapse rates for patients not treated with primaquine may
be this low. Randomized and controlled studies are needed to
prove the importance of this point.
Contacos et al. [79] treated 5 volunteers exposed to a Pak-
istani strain of P. vivax with the 5-day regimen, and all had
relapse within 181 days. Miller et al. [52] also tried this regimen
against the Salvador II strain of P. vivax, and the patient had
relapse at day 223. Singh et al. [82] recorded a relapse rate of
11% among 995 patients treated with the 5-day regimen, and
the relapse rate among 222 patients not treated with primaquine
was 9%. Rowland and Durrani [23] reported P. vivax relapse
rates of 52% and 51%, respectively, among 500 Pakistani pa-
tients randomized to receive treatment either with chloroquine
alone or with the 5-day, 15-mg regimen combined with chlo-
roquine. Gogtay et al. [83] and Yadav and Ghosh [84] reported
essentially similar findings from India. Villalobos-Salcedo and
colleagues [85] compared 60-day relapse rates among patients
in Amazonia treated with chloroquine and 15 mg of primaquine
daily given for 5 or 14 days: the odds of relapse among subjects
who received the 5-day regimen was 5.3 (95% CI, 0.9–40; P
! .03) (tables 5 and 6).
ACTIVITY AGAINST BLOOD-STAGE PARASITES
AND P. OVALE
Blood schizonticidal therapy. Primaquine is not recom-
mended as a stand-alone blood schizonticide, but its effect upon
blood-stage parasites should be understood. Primaquine mono-
therapy was shown to be effective against P. vivax parasitemia
in Thailand by Pukrittayakamee et al. [88], who administered
15 mg daily for 14 days to 30 patients, and parasitemia was
cleared in all. Wilairatana et al. [89] treated 23 patients infected
with P. vivax in Thailand with 30 mg of primaquine daily for
14 days, and all patients remained aparasitemic at day 28. These
studies demonstrate the apparently potent blood schizonticidal
activity of therapeutic doses of primaquine against P. vivax.
Therapeutic doses of primaquine do not affect the asexual
blood stages of P. falciparum. In eastern Indonesia, we found
no difference in activity of primaquine against P. falciparum in
25 subjects given chloroquine plus primaquine (30 mg daily
for 28 days) and in 28 given chloroquine plus a placebo of
primaquine [90]. In 1955, Arnold et al. [91] described complete
therapeutic failure of a primaquine regimen of 30 mg daily
against P. falciparum (Panama P-F-6 strain) in 6 volunteers.
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Table 4. Key confounders of the diagnosis of infection with primaquine-resistant Plasmodium vivax.
Confounder Ambiguity Solution
Noncompliance to prescribed therapy Adequacy of dose Supervise of therapy
Emesis of dose Adequacy of dose Supervise of therapy and readminister vomited doses
Parasite tolerance Resistance vs. tolerance Determine baseline susceptibility or use 30-mg regimen
Chloroquine resistance Recrudescence vs. relapse Relapse can be discounted if recurrence is !1 month
after the end of therapy; or use an alternative
therapy (e.g. quinine)
Reinfection Reinfection vs. relapse Evaluate repatriated traveler or, if necessary, evacuate
to an area where malaria is not endemic
Transmission-blocking therapy. A single dose of 45 mg of
primaquine is routinely prescribed for P. falciparum malaria in
areas where it is endemic, to reduce the risk of transmission.
In experimentally challenged volunteers, primaquine markedly
reduced the number of circulating gametocytes and sterilized
those remaining [92, 93]. This was an important finding, be-
cause effective blood schizonticidal treatment may leave sur-
viving gametocytes [94]. This result is especially problematic
when slow-acting antimalarials are used, because the brief pe-
riod of primaquine gametocytocidal activity precedes elimi-
nation of trophozoites that may differentiate to gametocytes.
In practice, a single dose of primaquine may accomplish little
[92, 93, 95]. Kaneko et al. [96] evaluated this regimen in a
village in Sumatra and documented reduced numbers of ga-
metocyte in patients treated with primaquine, but they did not
assess transmission to mosquitoes. Standard primaquine ther-
apy against P. vivax resulted in rapid (4–20 h) and complete
loss of transmission to mosquitoes in 5 patients infected with
P. vivax in Brazil [97].
P. ovale infection. This parasite occurs in West Africa, The
Philippines, eastern Indonesia, and New Guinea. The foci in
the Pacific have exceedingly low but consistent frequencies of
infection [98]. Diagnosis of P. ovale infection should be sup-
ported by agreement among expert microscopists or by mo-
lecular biological evidence [99, 100]. Primaquine therapy for
P. ovale infection is as for P. vivax infection. Therapeutic failure
of primaquine against P. ovale has been reported [101], but
only in patients who did not receive directly observed therapy.
TOLERABILITY AND TOXICITY
Gastrointestinal upset. We do not accept the view that pri-
maquine is toxic and poorly tolerated. Compared with other
antimalarials, it has good tolerability and safety in people con-
sidered good candidates to receive it. Lethal doses of 8-amino-
quinolines in animals exhibited pronounced hepatotoxicity
[31], and lesser doses showed hematological and gastrointes-
tinal effects, primarily epigastric discomfort [17, 102]. However,
studies of therapeutic doses demonstrate good tolerability and
safety. Clayman et al. [103] observed abdominal distress in hu-
man subjects who had fasted and received a single dose of
primaquine: it was reported by 5% of subjects who received a
15-mg dose, by 10% who received a 30-mg dose, 35% who
received a 60-mg dose, and 100% who received a 90-mg dose.
The drug was tolerated without complaint in subjects who had
eaten, even at the highest doses administered.
The 15-mg dose of primaquine consistently shows good tol-
erability [12, 14, 18], and few complaints occur at higher doses.
Clyde and McCarthy [33] administered 60 mg daily for 7 days
to 11 men and described the adverse effects as “negligible in 9
men, and 2 others consisted of moderate abdominal cramps
and nausea toward the end of the course” (p. 563). Baird et
al. [42] administered two 60-mg and one 30-mg dose concur-
rent with chloroquine therapy to 22 subjects in Indonesia; phys-
ical complaints were no more frequent than among 23 other
subjects receiving chloroquine and a placebo of primaquine.
Among 5 subjects given a 14-day, 30-mg regimen, Edgecomb
et al. [18] observed mild transient adverse effects in only 1
subject. In a trial of a regimen of 30 mg daily for prophylaxis
in Indonesia, 43 men continued taking the regimen for 1 full
year and had no more complaints that did 42 subjects who
received placebo [104]. Kenyan children tolerated the same
regimen for 12 weeks [105], as did another Indonesian group
taking 30 mg every other day for 16–19 weeks [106].
Methemoglobinemia. Primaquine consistently elevates the
methemoglobin level (typically !5 g%, and 112 g% is rare)
[31]. Fletcher et al. [107] reported elevation to 6.1 g/L (level
at baseline, 1.6 g/L) after a regimen of 15 mg daily for 14 days—
essentially the same as the level of 5.8 g% observed in Indo-
nesian subjects who received 30 mg daily for 52 weeks [105].
Methemoglobin levels of !20% are tolerated without symptoms
or signs [108], and we are not aware of patients receiving pri-
maquine who required treatment for methemoglobinemia. An
inborn deficiency of methemoglobin reductase greatly increases
the capacity for primaquine and other agents to induce clini-
cally relevant methemoglobinemia [109].
Glucose-6-phosphate dehydrogenase (G6PD) deficiency and
primaquine-induced hemolytic anemia. Primaquine causes
acute hemolysis in people with inborn G6PD deficiency. Among
G6PD-deficient Africans, treatment causes destruction primar-
ily of senescent erythrocytes and is therefore mild and self-
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Table 5. Rates of relapse of Plasmodium vivax malaria after primaquine therapy
at a dosage of 15 mg daily for 5 days.
Reference
Geographic
location
Supervised
therapy
No. of
patients
Duration of
follow-up,
months
Percentage
of patients
with relapse
[52] Central America Yes 1 9 100
[79] Pakistan Yes 5 7–11 100
[23] Pakistan No 250 12 51
[22] India Yes 725 12 7
[81] India No 995 8 10
[82] India No 6393 12 1
[83] India Yes 62 6 27
[86] India No 15,240 12 16
[87] India No 5541 12 9
Table 6. Summary of reports from India, Pakistan, and Brazil showing the therapeutic
efficacy of standard chloroquine in combination with 15 mg of primaquine daily for 5
or 14 days for treatment of Plasmodium vivax malaria.
Reference
Geographic
location
Primaquine
therapy given
No. of
patients
Relapse
rate, %
Therapeutic
efficacy,
% (95% CI)
[81] India None 222 9 …
[83] India None 60 12 …
[84] India None 723 9 …
[81] India 15 mg for 5 days 995 11 9.7 (21 to 3)
[83] India 15 mg for 5 days 62 27 …
[84] India 15 mg for 5 days 759 7 2.2 (3 to 7)
[83] India 15 mg for 14 days 63 0 100 (95 to 100)
[23] Pakistan None 350 51 …
[23] Pakistan 15 mg for 5 days 250 51 0 (8 to 8)
[23] Pakistan 15 mg for 14 days 100 32 37 (27 to 48)
[85] Brazil 15 mg for 5 days 30 27 NDa
[85] Brazil 15 mg for 14 days 31 7 …
a No data: relapse rate without primaquine therapy unknown.
limited, with recovery (with reticulocytosis) even if primaquine
therapy is continued [34]. The hemolytic effects in G6PD-de-
ficient subjects were either less severe or altogether absent using
either the 45-mg or 60-mg weekly dose for 8 weeks, compared
with the 15-mg regimen [34].
Many G6PD variants have been identified [110]. Some are
not associated with any hemolytic sensitivity, and others are
associated with life-threatening hemolytic episodes, such as the
Mediterranean B variant [111]. Primaquine causes largely
unpredictable degrees of severity of hemolysis among patients
with other variants, which may occur in any ethnic group.
G6PD variants associated with mild primaquine sensitivity,
such as African A, typically show 10%–20% of normal G6PD
activity, whereas variants associated with severe sensitivity, such
as Mediterranean A, show less than 5% of the normal activity.
Commercially available qualitative tests for G6PD deficiency
make diagnosis relatively easy [112, 113]. The inability to rou-
tinely assess G6PD status of a fetus in utero explains why preg-
nancy is a contraindication for primaquine therapy.
G6PD catalyzes the rate-limiting step in the hexose mono-
phosphate shunt, which drives reduction of glutathione. Di-
minished G6PD activity thus limits defenses against oxidative
damage. However, primaquine-induced hemolysis involves
more subtle effects than oxidative attack, because potent stim-
ulation of the hexose monophosphate shunt by primaquine
metabolites has been shown to occur independently of gluta-
thione redox equilibrium [111, 114].
CONCLUSIONS
1. The risk of relapse for vivax malaria ranges from 5%
to 80%.
2. The standard regimen of 15 mg daily for 14 days is
often not effective. A regimen of 30 mg for 14 days should be
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prescribed, or 0.5 mg/kg daily for 14 days for infants or people
weighing 170 kg.
3. Supervised compliance with prescribed therapy is nec-
essary to prove resistance.
4. Taking primaquine with food greatly improves its gas-
trointestinal tolerability.
5. Primaquine-induced methemoglobinemia is mild and
self-limited.
6. Therapeutic doses of primaquine are well tolerated and
not toxic in people considered good candidates to receive the
treatment.
7. Primaquine is dangerous with G6PD deficiency and
should not used without knowledge of G6PD status or during
pregnancy.
8. Standard primaquine therapy rapidly and completely
prevents development of P. vivax in mosquitoes (i.e., trans-
mission blocking).
9. A single 45-mg dose of primaquine adjunctive to ther-
apy for P. falciparum infection may not block transmission.
10. The 5-day, 15-mg regimen of primaquine is not ef-
fective against relapse of P. vivax malaria.
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